EUCLID VISION GROUP LIMITED

• ◆

  Audit opinion: Qualified

  Latest auditor's report carried a non-clean opinion.

1. EUCLID VISION GROUP LIMITED 2025-09-11 → present
2. ENNOVY GROUP LIMITED 2018-12-31 → 2025-09-11
3. DEALTFORCE LIMITED 1998-08-05 → 2018-12-31

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Buzzacott Audit LLP

Audit opinion

Qualified

Going concern

Affirmed

“The company and group's cash flow projections, taking account of reasonable possible changes in trading performance and available mitigating actions, show that the group and company will be able to operate within the limits of the available facilities for a period of at least 12 months from the date of signing these financial statements. For these reasons, the sole director considers it appropriate to continue to prepare the financial statements for the group and company on a going concern basis.”

Group structure

1. EUCLID VISION GROUP LIMITED · parent
   1. Mark'ennovy Personalized Care S.L. 100% · Spain
   2. Disop S.A. 100% · Spain
   3. Precision Technology Services Limited 100% · Canada
   4. KATT Design Group Limited 100% · Canada
   5. Medmont International Pty Limited 95% · Australia
   6. mark'ennovy Personalized Care Limited 100% · UK
   7. Vista Optics Limited 100% · UK
   8. mark'ennovy Material Sciences Limited 100% · UK
   9. mark'ennovy GmbH 100% · Germany
   10. mark'ennovy srl 100% · Italy

Significant events

• “In March 2024, the Company acquired 95% of the equity and voting power in Medmont through its wholly owned subsidiary EVG Australia.”
• “In March 2024, the Company acquired 100% of KATT and PTS.”
• “Moving, in November 2023, to a new manufacturing plant of lathed lenses in Madrid for the expansion and improvement of this line of business, which is allowing the expansion of this business through access to cutting-edge technology plant.”
• “Automation of machines to improve processes and increase the production of lens care solutions.”
• “Development and launch of MYLO Toric which has had a positive impact on sales.”
• “Under work third year MYLO efficacy that was published in the prestigious American Journal of Ophthalmology in 2025. Results also presented at BCLA congress increasing visibility of the product.”
• “Fourth year data for Mylo efficacy was completed. PMCFU.”
• “TF-02 (silicone hydrogel) was audited by the Notified Body and the MDR certification achieved.”
• “In June 2025, Cristian Ostrowski, CEO of the Group, resigned.”
• “On 11 August 2025 all existing A ordinary shares, C1 ordinary shares. C2 ordinary shares, D ordinary shares and preferred shares have been redesignated into an aggregate number of 223,172 ordinary shares with a nominal value of £0.00001 each.”
• “On September 11, 2025, Ennovy Group Limited changed its name to Euclid Vision Group Limited.”
• “In October 2025, the UK subsidiary, Mark'ennovy Material Sciences Limited, closed permanently; this company had been inactive since 2022.”
• “In November 2025, the Swiss branch of Mark'ennovy Personalized Care, S.L. closed permanently; this branch had been inactive since February 2024, when the business was transferred to a distributor.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +23%

  £29,765,747 → £36,606,560

• Cash

  +235.1%

  £1,233,113 → £4,132,644

• Net assets

  +24.1%

  £30,736,916 → £38,159,850

• Employees

  +27.4%

  248 → 316

• Operating profit

  -449.6%

  -£4,246,280 → -£23,336,293

• Profit before tax

  -441.1%

  -£4,350,668 → -£23,540,017

• Wages

  +17.2%

  £11,530,909 → £13,512,644

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers